
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3483355/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2014, 106, dju124.	3.0	2,202
2	Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1204-1212.	1.1	519
3	Molecular targeted therapies: Ready for "prime time―in biliary tractÂcancer. Journal of Hepatology, 2020, 73, 170-185.	1.8	226
4	Simple prognostic score for metastatic castrationâ€resistant prostate cancer with incorporation of neutrophilâ€toâ€lymphocyte ratio. Cancer, 2014, 120, 3346-3352.	2.0	128
5	Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. European Journal of Cancer, 2014, 50, 1581-1589.	1.3	119
6	HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?. Cancer and Metastasis Reviews, 2017, 36, 141-157.	2.7	119
7	Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective study. European Journal of Cancer, 2013, 49, 329-335.	1.3	104
8	Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials. Journal of the National Cancer Institute, 2020, 112, 200-210.	3.0	90
9	Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Annals of Oncology, 2016, 27, 134-140.	0.6	88
10	Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. European Journal of Pharmacology, 1999, 364, 123-132.	1.7	85
11	Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression. Journal of Neuro-Oncology, 2014, 117, 147-152.	1.4	83
12	Emerging Biomarkers in Glioblastoma. Cancers, 2013, 5, 1103-1119.	1.7	80
13	Neutrophil–lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival. Journal of Neuro-Oncology, 2017, 132, 463-471.	1.4	78
14	<p>Biliary tract cancers: current knowledge, clinical candidates and future challenges</p> . Cancer Management and Research, 2019, Volume 11, 2623-2642.	0.9	78
15	18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. Journal of Hepatology, 2019, 71, 115-129.	1.8	76
16	Lipids and essential fatty acids in patients presenting with self-harm. British Journal of Psychiatry, 2007, 190, 112-117.	1.7	75
17	Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treatment Reviews, 2020, 84, 101936.	3.4	73
18	Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma—a meta-analysis. European Journal of Cancer, 2018, 105, 1-9.	1.3	69

#	Article	IF	CITATIONS
19	Some behavioural and neurochemical aspects of subacute (±)3,4-methylenedioxymethamphetamine administration in rats. Pharmacology Biochemistry and Behavior, 1995, 52, 479-484.	1.3	68
20	Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. Journal of Neuro-Oncology, 2015, 124, 119-126.	1.4	67
21	Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. Cancer Treatment Reviews, 2020, 89, 102084.	3.4	61
22	Acute 3,4-methylenedioxymethamphetamine (MDMA) administration produces a rapid and sustained suppression of immune function in the rat. Immunopharmacology, 1998, 38, 253-260.	2.0	57
23	Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair. Cancer Treatment Reviews, 2018, 70, 168-177.	3.4	55
24	Emergence of MRSA in positive blood cultures from patients with febrile neutropenia—a cause for concern. Supportive Care in Cancer, 2008, 16, 1085-1088.	1.0	48
25	A phase II trial of secondâ€line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. Cancer, 2015, 121, 1620-1627.	2.0	47
26	Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?. Cancer Treatment Reviews, 2016, 44, 26-41.	3.4	45
27	Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. Cancer Treatment Reviews, 2021, 99, 102258.	3.4	45
28	Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres. World Journal of Gastroenterology, 2019, 25, 5991-6005.	1.4	43
29	Germline mutations in pancreatic cancer and potential new therapeutic options. Oncotarget, 2017, 8, 73240-73257.	0.8	40
30	Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis. Nature Communications, 2021, 12, 7336.	5.8	40
31	Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study. Expert Review of Gastroenterology and Hepatology, 2018, 12, 723-731.	1.4	37
32	Swim Stress Increases the Potency of Glycine at the N-Methyl-d-Aspartate Receptor Complex. Journal of Neurochemistry, 2002, 64, 925-927.	2.1	36
33	Outcome of Adjuvant Therapy in Biliary Tract Cancers. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 382-387.	0.6	36
34	Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. Scientific Reports, 2019, 9, 11610.	1.6	36
35	BIMT 17: a putative antidepressant with a fast onset of action?. Psychopharmacology, 1997, 134, 378-386.	1.5	34
36	Antiangiogenic therapies in glioblastoma multiforme. Expert Review of Anticancer Therapy, 2012, 12, 643-654.	1.1	29

#	Article	IF	CITATIONS
37	PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. Oncotarget, 2018, 9, 14922-14938.	0.8	29
38	Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas. Journal of the National Cancer Institute, 2017, 109, djw277.	3.0	28
39	Telotristat ethyl: a new option for the management of carcinoid syndrome. Expert Opinion on Pharmacotherapy, 2016, 17, 2487-2498.	0.9	27
40	Patterns of care and treatment outcomes in older patients with biliary tract cancer. Oncotarget, 2015, 6, 44995-45004.	0.8	27
41	Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era. Journal of Neuro-Oncology, 2014, 117, 153-160.	1.4	26
42	Pancreatic cancer: Are "liquid biopsies" ready for prime-time?. World Journal of Gastroenterology, 2016, 22, 7175.	1.4	25
43	Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 163, 103328.	2.0	25
44	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. Journal of Hepatology, 2020, 73, 1109-1117.	1.8	25
45	State-of-the-art in the management of locally advanced and metastatic gallbladder cancer. Current Opinion in Oncology, 2013, 25, 425-431.	1.1	24
46	Sequence Dependence of MEK Inhibitor AZD6244 Combined with Gemcitabine for the Treatment of Biliary Cancer. Clinical Cancer Research, 2013, 19, 118-127.	3.2	24
47	Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy. World Journal of Gastroenterology, 2016, 22, 6065.	1.4	23
48	Extrapulmonary poorly differentiated NECs, including molecular and immune aspects. Endocrine-Related Cancer, 2020, 27, R219-R238.	1.6	22
49	Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2017, 18, 909.	1.8	21
50	Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. Cancers, 2018, 10, 17.	1.7	21
51	Clinical and Translational Research Challenges in Biliary Tract Cancers. Current Medicinal Chemistry, 2020, 27, 4756-4777.	1.2	21
52	The importance of quality-of-life management in patients with advanced pancreatic ductal adenocarcinoma. Current Problems in Cancer, 2018, 42, 26-39.	1.0	20
53	Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a preâ€specified subgroup analysis of the randomized CASSINI study. Cancer Medicine, 2020, 9, 6196-6204.	1.3	20
54	Use and Misuse of Waterfall Plots. Journal of the National Cancer Institute, 2014, 106, .	3.0	19

#	Article	IF	CITATIONS
55	Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer. European Journal of Cancer, 2015, 51, 1381-1388.	1.3	19
56	Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy. British Journal of Cancer, 2022, 126, 693-705.	2.9	18
57	Detection of Early Tumor Response to Axitinib in Advanced Hepatocellular Carcinoma by Dynamic Contrast Enhanced Ultrasound. Ultrasound in Medicine and Biology, 2016, 42, 1303-1311.	0.7	17
58	Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma. Current Oncology Reports, 2017, 19, 50.	1.8	17
59	Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592091529.	1.4	17
60	Health-related quality of life, anxiety, depression and impulsivity in patients with advanced gastroenteropancreatic neuroendocrine tumours. World Journal of Gastroenterology, 2018, 24, 671-679.	1.4	17
61	The effect of acute MDMA administration on body temperature, serum corticosterone and neurotransmitter concentrations in male and female rats. Human Psychopharmacology, 1995, 10, 373-383.	0.7	16
62	3,4-methylenedioxymethamphetamine (MDMA; Ecstasy) administration produces dose-dependent neurochemical, endocrine and immune changes in the rat. Human Psychopharmacology, 1999, 14, 95-104.	0.7	16
63	Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. BMC Cancer, 2017, 17, 262.	1.1	16
64	Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial. TH Open, 2020, 04, e107-e112.	0.7	16
65	The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer. Cancers, 2021, 13, 3779.	1.7	16
66	A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). Oncologist, 2021, 26, e669-e678.	1.9	15
67	NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). Future Oncology, 2020, 16, 1069-1081.	1.1	15
68	The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers. PLoS ONE, 2018, 13, e0206007.	1.1	14
69	Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery. Surgical Oncology, 2016, 25, 223-228.	0.8	13
70	Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer. Pancreatology, 2020, 20, 1682-1688.	0.5	13
71	Chronic imipramine treatment upregulates IR2-imidazoline receptive sites in rat brain. Neurochemistry International, 1997, 30, 101-107.	1.9	12
72	Treatment Outcomes in 1p19q Co-deleted/Partially Deleted Gliomas. Canadian Journal of Neurological Sciences, 2017, 44, 288-294.	0.3	12

#	Article	IF	CITATIONS
73	Long term responders to palliative chemotherapy for advanced biliary tract cancer. Journal of Gastrointestinal Oncology, 2017, 8, 352-360.	0.6	12
74	Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs). Cancers, 2020, 12, 1988.	1.7	12
75	The assessment of pancreatic exocrine function in patients with inoperable pancreatic cancer: In need of a new gold-standard. Pancreatology, 2020, 20, 668-675.	0.5	12
76	A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2013, 31, 314-314.	0.8	12
77	Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib. Clinical and Translational Oncology, 2017, 19, 364-372.	1.2	11
78	Irreversible Electroporation in pancreatic ductal adenocarcinoma: IsÂthere a role in conjunction with conventional treatment?. European Journal of Surgical Oncology, 2018, 44, 1486-1493.	0.5	11
79	Adjuvant chemotherapy and outcomes in patients with nodal and resection marginâ€negative pancreatic ductal adenocarcinoma: A systematic review and metaâ€analysis. Journal of Surgical Oncology, 2019, 119, 932-940.	0.8	11
80	NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). BMJ Open, 2020, 10, e034527.	0.8	11
81	Management of glioblastoma in the elderly. Clinical Advances in Hematology and Oncology, 2012, 10, 379-86.	0.3	11
82	Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary. British Journal of Cancer, 2022, 127, 531-540.	2.9	11
83	Anaplastic Oligodendroglioma: Advances and Treatment Options. Current Treatment Options in Neurology, 2013, 15, 289-301.	0.7	10
84	Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient management. CNS Oncology, 2013, 2, 351-358.	1.2	10
85	Predictive and prognostic values of ERCC1 and XRCC1 in biliary tract cancers. Journal of Clinical Pathology, 2016, 69, 695-701.	1.0	10
86	18F-FLT PET imaging of cellular proliferation in pancreatic cancer. Critical Reviews in Oncology/Hematology, 2016, 99, 158-169.	2.0	10
87	Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice. Journal of Clinical Medicine, 2019, 8, 1630.	1.0	10
88	A strategy for early detection of response to chemotherapy drugs based on treatment-related changes in the metabolome. PLoS ONE, 2019, 14, e0213942.	1.1	10
89	Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC). Clinical and Translational Oncology, 2019, 21, 950-953.	1.2	9
90	NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials. Medical Oncology, 2020, 37, 61.	1.2	9

#	Article	IF	CITATIONS
91	Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets. Oncology Research and Treatment, 2018, 41, 298-304.	0.8	8
92	Systemic therapies in advanced hepatocellular carcinoma: How do older patients fare?. European Journal of Surgical Oncology, 2021, 47, 583-590.	0.5	7
93	Targeted Therapies for Perihilar Cholangiocarcinoma. Cancers, 2022, 14, 1789.	1.7	7
94	Outcomes in patients ≥ 80Âyears with a diagnosis of a hepatopancreaticobiliary (HPB) malignancy. Medical Oncology, 2019, 36, 85.	1.2	6
95	Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. Cancer Treatment Reviews, 2021, 94, 102168.	3.4	6
96	Some behavioural and neurochemical effects of ipsapirone in two rodent models of depression. Journal of Psychopharmacology, 1996, 10, 126-133.	2.0	5
97	Clioblastoma Treatment in the Elderly in the Temozolomide Therapy Era. Canadian Journal of Neurological Sciences, 2014, 41, 357-362.	0.3	5
98	Fibrolamellar carcinoma: Challenging the challenge. European Journal of Cancer, 2020, 137, 144-147.	1.3	5
99	Outcomes in older patients with biliary tract cancer. European Journal of Surgical Oncology, 2021, 47, 569-575.	0.5	5
100	HPB cancers in older patients inclusion of older/senior patients in clinical trials. European Journal of Surgical Oncology, 2021, 47, 597-602.	0.5	4
101	Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?. Cancers, 2021, 13, 4152.	1.7	4
102	The Potential Role of Liquid Biopsies in Advancing the Understanding of Neuroendocrine Neoplasms. Journal of Clinical Medicine, 2021, 10, 403.	1.0	4
103	Selumetinib (Sel) and cisplatin/gemcitabine (CisGem) for advanced biliary tract cancer (BTC): A randomized trial Journal of Clinical Oncology, 2018, 36, 4084-4084.	0.8	4
104	Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours. World Journal of Clinical Oncology, 2020, 11, 205-216.	0.9	4
105	Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy. Acta Oncológica, 2022, 61, 583-590.	0.8	4
106	Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence. Annals of Surgical Oncology, 2022, 29, 5568-5577.	0.7	4
107	Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems. Future Oncology, 2016, 12, 2561-2578.	1.1	3
108	"lf You Prick Us, Do We Not Bleed?―Whom Should We Choose?. Journal of Clinical Oncology, 2016, 34, 513-514.	0.8	3

#	Article	IF	CITATIONS
109	Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes. Cancer Management and Research, 2019, Volume 11, 7537-7556.	0.9	3
110	Effects of statin, aspirin, or metformin use on recurrence free and overall survival in patients with biliary tract cancer (BTC) Journal of Clinical Oncology, 2014, 32, 303-303.	0.8	3
111	Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. Cancer Treatment Reviews, 2021, 101, 102299.	3.4	3
112	Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. European Journal of Surgical Oncology, 2022, 48, 1198-1208.	0.5	3
113	Elderly patients diagnosed with hepatopancreatobiliary malignancies: A challenge beyond resection. Cancer, 2017, 123, 888-890.	2.0	2
114	Molecular Profiling of Well-Differentiated Neuroendocrine Tumours: The Role of ctDNA in Real-World Practice. Cancers, 2022, 14, 1017.	1.7	2
115	Use of the Rockwood Clinical Frailty Scale in patients with advanced hepatopancreaticobiliary malignancies. Expert Review of Anticancer Therapy, 2022, 22, 1009-1015.	1.1	2
116	Royal academy of medicine in Ireland section of biomedical sciences. Irish Journal of Medical Science, 1994, 163, 258-268.	0.8	1
117	Response to letter â€~Outcome of second-line chemotherapy for biliary tract cancer'. European Journal of Cancer, 2013, 49, 1512-1513.	1.3	1
118	To BRCA or Not to PALB. Journal of Clinical Oncology, 2015, 33, 2581-2582.	0.8	1
119	Neutrophil/lymphocyte ratio (NLR) as a prognostic factor in biliary tract cancer (BTC) Journal of Clinical Oncology, 2013, 31, 4130-4130.	0.8	1
120	Do recurrent and de novo metastatic biliary tract cancer patients have the same outcome on treatment?. Journal of Clinical Oncology, 2015, 33, 351-351.	0.8	1
121	Carboplatin-etoposide chemotherapy for patients with advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC); outcomes from a European Neuroendocrine Tumour Society Centre of Excellence. Endocrine Abstracts, 0, , .	0.0	1
122	Patterns of care and treatment outcomes in older patients with biliary tract cancer Journal of Clinical Oncology, 2014, 32, 315-315.	0.8	1
123	Royal academy of medicine in ireland section of biomedical sciences. Irish Journal of Medical Science, 1995, 164, 311-319.	0.8	Ο
124	Royal academy of medicine in ireland section of biomedical sciences. Irish Journal of Medical Science, 1996, 165, 224-238.	0.8	0
125	Royal academy of medicine in Ireland section of biomedical sciences. Irish Journal of Medical Science, 1998, 167, 51-63.	0.8	0
126	Temozolomide for 1P19Q Co-Deleted and Partially Deleted Gliomas. Annals of Oncology, 2014, 25, iv138.	0.6	0

8

#	Article	IF	CITATIONS
127	Systemic therapy for hepatocellular carcinoma. Hepatic Oncology, 2014, 1, 23-38.	4.2	0
128	RT-19 * PROGNOSTIC VALUE OF EARLY CHANGES IN NEUTROPHIL AND LYMPHOCYTE MEASURES DURING CHEMORADIOTHERAPY FOR GLIOBLASTOMA. Neuro-Oncology, 2014, 16, v191-v191.	0.6	0
129	RT-20 * DELAYING RADIOTHERAPY IN 1p19q CO-DELETED AND PARTIALLY DELETED GLIOMAS. Neuro-Oncology, 2014, 16, v191-v191.	0.6	Ο
130	The dark side of T1 non-appendiceal small bowel neuroendocrine tumors. Human Pathology, 2017, 66, 239-240.	1.1	0
131	Emerging facets in the treatment of patients with hepatopancreaticobiliary malignancies. Current Problems in Cancer, 2018, 42, 8-11.	1.0	0
132	Response to: Assessing the risk of bias and publication bias should be integral parts of the systematic review. European Journal of Cancer, 2019, 118, 189.	1.3	0
133	Response to letter to the editor: The impact of the nodal status and resection margin on the effectiveness of adjuvant chemotherapy for pancreatic cancer: It calls for more careful evaluation. Journal of Surgical Oncology, 2019, 120, 1055-1055.	0.8	0
134	In Reply. Oncologist, 2021, 26, e903-e904.	1.9	0
135	Population profile for squamous cell carcinoma and adenocarcinoma of cervix in Waterford Regional Hospital, Ireland Journal of Clinical Oncology, 2010, 28, e15557-e15557.	0.8	0
136	Retrospective review of patients with a diagnosis of testicular germ cell tumor seen in Waterford Regional Hospital, Ireland, in a 5.5-year period Journal of Clinical Oncology, 2011, 29, e15111-e15111.	0.8	0
137	Feasibility and potential benefits of second-line chemotherapy in patients with advanced biliary tract cancer Journal of Clinical Oncology, 2012, 30, 338-338.	0.8	0
138	Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective study Journal of Clinical Oncology, 2012, 30, e14524-e14524.	0.8	0
139	Outcome of adjuvant therapy for biliary tract cancers Journal of Clinical Oncology, 2012, 30, e14592-e14592.	0.8	0
140	Effect of body mass index on outcomes in biliary tract cancer Journal of Clinical Oncology, 2015, 33, 399-399.	0.8	0
141	Prognostic score in high-grade gastrointestinal neuroendocrine tumours (GI-NETs) Journal of Clinical Oncology, 2015, 33, 4089-4089.	0.8	0
142	Editorial comment on: development and external validation of a model to predict overall survival in patients with resected gallbladder cancer. Hepatobiliary Surgery and Nutrition, 2021, 11, 0-0.	0.7	0
143	RELEVANT study: Patient (Pt) and physician (PI) perspectives on meaningful outcomes in advanced pancreatic ductal adenocarcinoma (PDAC) Journal of Clinical Oncology, 2020, 38, 150-150.	0.8	0
144	Distal migration of a partially covered duodenal stent requiring emergency surgical extraction. International Journal of Gastrointestinal Intervention, 2022, 11, 89-93.	0.1	0